

Curriculum Vitae

(86) 138-2197-4012 672412336@qq.com

Personal information:

Name: Xinglan Gong Date of birth: 1987.9 Gender: Female Residence, dwelling: Tianjin, China

Job application intention:

Medical Translator (EN-CN; CN-EN)

Education background:

2006.09~2011.7	Tianjin University of Traditional Chinese Medicine	Clinical Medicine	Bachelor of Medicine
2011.09~2013.7	Tianjin University of Traditional Chinese Medicine	Clinical Medicine	Master of Medicine

Speciality:

1. Professional skill: Medicine (certified doctor)
2. Languages: English-Chinese; Chinese-English
3. Software: SDL Trados Studio 2024; memoQ

Recent work :

1. 2013.9- 2015.7, employed in the Department of Neurology of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
 2. 2015-, freelance medical translator. Proficient in using Trados software and memoQ software, experienced in MTPE projects, translating about 30 million English words. Areas of expertise: preclinical and clinical data for drug registration, such as preclinical pharmacology and toxicology research data, clinical safety and efficacy studies, clinical pharmacology studies, clinical pharmacokinetics studies, expert reports, periodic safety update reports (PSUR), clinical trial protocols, and investigator brochures (IBs), etc.
-

Some of the projects I have translated see next page:

Some of the projects I have translated are as follows

Project Name	Vendor	Word count
Axitinib 2021 PBRER_for translation	Pfizer	31638
KN407 China CSR 16.2 listings-lm	Pfizer	74874
Bosutinib 2021 DSUR inc FDA	Pfizer	84740
7684A-006 Protocol English 08 Dec 2021	Merck Sharp & Dohme Corp.	15098
MK-4830-INVESTIGATOR'S BROCHURE	Merck Sharp & Dohme Corp.	23623
KEYNOTE-355-statistical-report-tnbc-FA	Merck Sharp & Dohme Corp.	14368
Novartis QIAGEN Schedule 5 (Final) 2021 06 24 Partially Executed_JL-encrypted	NOVARTIS	33860
COAV101A12303 Study Report Body [ICH E3]	NOVARTIS	49650
LNP023 PNH Breakthrough Designation Final	NOVARTIS	7658
IB BAY 1753011_V5.0	Bayer	50343
Integrated Analysis Plan (iAP) for Safety/RMP/Benefit-Risk of Encorafenib + Binimetinib in Chinese Subjects with BRAF V600E-mutant metastatic Non-Small Cell Lung Cancer	Pierre Fabre	9442
Nonclinical Overview	Kinnate Biopharma, Inc.	16100
Briefing Document - Schizophrenia - PMDA Pre-Phase 1 Consultation	Teva Branded Pharmaceutical Products R&D, Inc.	19987
pralsetinib cRMP 2.0 Published Output	Gavreto	14772
SD-809 DSUR - 17Jul2019 to 16Jul2020	Teva Branded Pharmaceutical Products R&D, Inc.	39199
IN_TPZ_R01 PVM-215-FORM 03-RMPT-RMP-ver6.0_eng	HK inno.N Corporation	31271
TJ033721_Clinical_Monitoring_Plan_Version 2.0	Michi Sprague Clinical Research Associate	49410
Avelumab 2021 DSUR inc FDA	Affiliates of Merck KGaA, Darmstadt, Germany	16264
clinical-overview	Genentech	31418
Afatinib HNSCC_1200.161_Pre-NDA Meeting Request	Boehringer Ingelheim International GmbH	18189
V114-Canada-EOP2-Consolidated-BP	Merck Canada, Inc.	36728